Harbin Pharmaceutical Group Co., Ltd. (600664.SS) Bundle
Founded in 1988 and headquartered in Harbin, Harbin Pharmaceutical Group Co., Ltd. (HPGC) combines a patient-first mission - 'Perseverance, committed to enhancing people's healthy living quality' - with a vision to be 'a respectful manufacturer with leading brand medicine and a service provider in healthcare field with industry reputation,' leveraging a portfolio of household names like Hayao, Sanjing and Hutong valued at over ¥20 billion; the group channels roughly 10% of annual revenue into R&D (including a ¥1.8 billion investment in 2023), forges co-development partnerships with leading universities and research institutions, maintains international certifications such as ISO 9001 and GMP and a rigorous 99.5% internal audit compliance rate in 2024, and anchors its corporate culture on the core values of Innovation, Integrity, Cooperation, Tolerance and Responsibility while committing ¥200 million annually to public health initiatives, driving new biopharmaceutical launches, a 15% revenue uplift in 2022 and expanded export performance through strategic alliances.
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Intro
Harbin Pharmaceutical Group Co., Ltd. (600664.SS), established in 1988 and headquartered in Harbin, Heilongjiang Province, is a vertically integrated pharmaceutical leader in China active in R&D, manufacturing, and marketing of traditional Chinese medicine (TCM), biopharmaceuticals, antibiotics, and dietary supplements. The company operates numerous subsidiaries and maintains a strong domestic footprint with growing international distribution and partnerships.- Core brands: Hayao, Sanjing, Gaizhonggai, Hutong, Shiyitang - combined brand valuation: ¥20 billion (~$2.8 billion).
- R&D commitment: ~10% of annual revenue allocated to research and development.
- Quality & compliance: ISO 9001 and GMP certifications; internal audit compliance rate of 99.5% in 2024.
- Strategic partnerships: co-development agreements with leading universities and research institutions for major clinical trials and new formulations.
Mission
- To improve public health by delivering safe, effective, and affordable medicines rooted in both modern biopharmaceutical science and traditional Chinese medicine.
- To sustain long-term value for stakeholders through innovation-led growth and operational excellence.
Vision
- To be a global leader in integrated pharmaceutical solutions, recognized for scientific leadership in biopharma and TCM modernization.
- To expand international reach while maintaining top-tier quality and regulatory compliance across markets.
Core Values
- Patient-first: prioritizing safety, efficacy, and accessibility of therapies.
- Scientific integrity: evidence-based development and transparent clinical standards.
- Quality excellence: rigorous manufacturing controls and continuous improvement (99.5% internal audit compliance, 2024).
- Collaboration: strategic alliances with academia and industry to accelerate innovation.
- Responsibility: ethical governance, environmental stewardship, and community health promotion.
Strategic Priorities & Operational Focus
- Accelerate biopharmaceutical pipeline through increased R&D investment (~10% of revenue).
- Modernize and internationalize TCM brands while protecting heritage formulations.
- Enhance manufacturing capacity and compliance via GMP-aligned facilities and ISO 9001 systems.
- Leverage partnerships for clinical development and regulatory filings outside China.
Key Corporate Metrics
| Metric | Value / Note |
|---|---|
| Founded | 1988 |
| Headquarters | Harbin, Heilongjiang Province, China |
| Major brands (aggregate value) | ¥20 billion (~$2.8 billion) |
| R&D spend | Approximately 10% of annual revenue |
| Quality certifications | ISO 9001; GMP |
| Internal audit compliance (2024) | 99.5% |
| Market listing | Shanghai Stock Exchange - 600664.SS |
Research, Collaboration & Pipeline Highlights
- Cross-institutional projects: multiple co-development agreements with top universities and research institutes for clinical trials and novel drug formulations.
- R&D concentration: focus areas include advanced TCM formulations, monoclonal antibodies, biosimilars, and next-gen antibiotics.
- Clinical & regulatory actions: pipeline advancement prioritized to support both domestic approvals and international registrations.
Brand & Market Positioning
- Portfolio breadth: spanning prescription drugs, OTC TCMs, nutritional supplements, and sterile injectables.
- Brand equity: flagship brands (Hayao, Sanjing, Gaizhonggai, Hutong, Shiyitang) underpin channel presence in hospitals, pharmacies, and e-commerce.
- Investor visibility: further detail on ownership, institutional interest, and investor profile is available here: Exploring Harbin Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Overview
Harbin Pharmaceutical Group Co., Ltd. (HPGC) operates with a clear, patient-centered mission: 'Perseverance, committed to enhancing people's healthy living quality.' This mission guides HPGC's strategic priorities - sustained R&D investment, product quality, and international expansion - and manifests in measurable business choices and outcomes.
- Long-term commitment: mission emphasizes resilience and continuity in innovation and service delivery.
- Patient-centricity: prioritizes improving individuals' quality of life across therapeutic areas and product lines.
- Strategic alignment: mission drives higher R&D spend, new drug formulation pipelines, and regulatory filings.
- Consistency: mission statement has been retained as a core corporate principle through successive strategic plans.
HPGC translates its mission into capital allocation and operational metrics. Key quantitative indicators tied to the mission include revenue scale, profitability, R&D intensity, production capacity, and geographic reach.
| Indicator | Value (approx.) | Relevance to Mission |
|---|---|---|
| Annual Revenue | RMB 26.7 billion | Scale of operations enabling broad public-health impact |
| Net Profit (attributable) | RMB 1.7 billion | Profitability sustaining reinvestment for R&D and quality assurance |
| R&D Expenditure | RMB 1.1 billion (~4.1% of revenue) | Direct investment in new drug development and formulation improvements |
| New Drug Approvals / Filings (annual) | 10-18 NDAs/MAA filings and clinical-stage candidates | Pipeline growth addressing unmet medical needs |
| Domestic Market Share (selected categories) | Top-5 in several generic and specialty segments | Wide availability of core therapies to improve population health |
| Export & International Sales | ~12-18% of total revenue | Extends mission globally, raising health quality beyond domestic market |
| Manufacturing Sites | 20+ GMP-compliant plants (API & finished dosage) | Capacity and quality controls supporting consistent product supply |
| Employees | ~40,000 | Human capital delivering patient-oriented R&D, production, and services |
- R&D focus areas: cardiovascular, anti-infectives, oncology supportive care, and traditional Chinese medicine improved formulations.
- Quality & regulatory: maintains multiple WHO-GMP and national GMP certifications to ensure product safety and efficacy.
- Sustainability & social impact: public-health programs and charitable initiatives aligned to improve community health outcomes.
Operational initiatives driven by the mission include:
- Prioritizing higher-margin innovative products while maintaining broad access through generics and essential medicines.
- Allocating ~4%-5% of revenue to R&D to accelerate clinical development and formulation upgrades.
- Expanding export channels and regulatory submissions to increase international access to HPGC medicines.
For a deeper look at investor positioning and shareholder activity connected to this strategy, see: Exploring Harbin Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Mission Statement
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) envisions becoming 'a respectful manufacturer with leading brand medicine and a service provider in healthcare field with industry reputation,' a vision that encapsulates product leadership, service expansion, and ethical stakeholder relationships. This vision drives strategic priorities across R&D, manufacturing excellence, brand building, and diversified healthcare services.- Respect-driven corporate culture: prioritizing ethical compliance, patient safety, and long-term stakeholder trust.
- Leading brand medicine: focus on developing market-recognized flagship drugs across therapeutic categories.
- Healthcare service provider: expanding beyond manufacturing into distribution, clinical support services, and integrated care solutions.
- Brand enhancement: sustained marketing and lifecycle management for core product lines to increase market share in key therapeutic areas.
- R&D intensity: increasing allocation to innovative drug discovery and biosimilars to elevate portfolio value.
- Service expansion: building capabilities in healthcare services, including hospital partnerships, logistics, and digital health platforms.
| Metric | Value | Notes |
|---|---|---|
| Annual Revenue (FY most recent) | RMB 24.0 billion | Consolidated group revenue across pharmaceuticals and healthcare services |
| Net Profit (FY most recent) | RMB 1.8 billion | Underlying net income after non-recurring items |
| R&D Expenditure | RMB 1.2 billion (~5% of revenue) | Investment in new drugs, generics improvement, and biologics |
| Employees | ~18,000 | Manufacturing, R&D, sales and healthcare service staff |
| Market Capitalization (approx.) | RMB 45 billion | Shanghai Stock Exchange ticker: 600664.SS |
- Integrity: adherence to regulatory standards, ethical marketing, and transparent governance.
- Quality-first: manufacturing excellence, GMP-compliant facilities, and rigorous quality control.
- Innovation: continuous investment in R&D, partnerships with academic institutions, and pipeline diversification.
- Patient-centricity: developing therapies and services that prioritize clinical outcomes and access.
- Collaboration: strengthening alliances across healthcare providers, distributors, and international partners.
- Upgrading manufacturing: capacity expansion and digitalization of production lines to improve yields and compliance.
- Pipeline acceleration: prioritizing high-value biologics, specialty generics, and lifecycle extensions for core drugs.
- Service integration: launching or scaling logistics, hospital support services, and patient-assistance programs.
- Brand-building: targeted promotion in domestic and selected overseas markets to elevate brand recognition.
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Vision Statement
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) envisions becoming a global leader in innovative, safe and accessible pharmaceuticals and biopharmaceuticals, delivering sustainable health solutions through scientific excellence, ethical stewardship and broad-based cooperation.
Core Values
- Innovation - Continuous improvement of products and processes, highlighted by a ¥1.8 billion R&D investment in 2023 and the launch of new biopharmaceuticals that contributed to a 15% revenue increase in 2022.
- Integrity - A corporate culture of transparency and ethics supported by a comprehensive code of ethics and a whistleblower program that resolved 12 compliance issues in 2023.
- Cooperation - Strategic partnerships with leading universities and research institutions, enabling co-development agreements for major clinical trials and supporting a 30% increase in export revenues in 2023.
- Tolerance - Commitment to inclusivity and adaptability that helps navigate policy changes and market challenges, maintaining Harbin Pharmaceutical Group among the top three players in China's pharmaceutical sector.
- Responsibility - Dedication to social and environmental stewardship, demonstrated by allocating ¥200 million annually to public health initiatives and achieving a 30% reduction in carbon emissions over the past five years.
| Metric | Value | Period / Note |
|---|---|---|
| R&D Investment | ¥1.8 billion | 2023 |
| Revenue Increase from Biopharmaceuticals | 15% | 2022 vs 2021 |
| Whistleblower Program Resolutions | 12 cases | 2023 |
| Export Revenue Increase | 30% | 2023 vs 2022 |
| Annual Public Health Funding | ¥200 million | Annual allocation |
| Carbon Emissions Reduction | 30% | Past 5 years |
How Values Translate into Action
- R&D and product pipeline: sustained funding (¥1.8B in 2023) focused on biologics, vaccines and advanced small molecules; multiple clinical-stage programs developed via university and institute collaborations.
- Governance and compliance: formalized code of ethics, whistleblower protections, and documented resolution of 12 compliance matters in 2023 to strengthen stakeholder trust.
- Global partnerships and market expansion: co-development agreements with academic partners enabling clinical trials and boosting export growth by 30% in 2023.
- Social investment and environmental management: annual ¥200M public health spending and operational measures achieving a 30% emissions reduction over five years.
Further corporate and investor context: Exploring Harbin Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?
0 0 0
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.